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Abstract:
Background:
Carotid artery disease is not just a causal risk factor of ischemic stroke, but may predispose patients to depressive symptoms and low
health related quality of life (HRQoL).
Objectives:
The  objectives  of  the  present  study  were  to  assess  the  association  between  severe  carotid  artery  stenosis  (CAS)  and  cognitive
impairment, frequency of depressive symptoms and status of HRQoL.
Methods:
Cross - sectional study involved 55 patients with severe CAS and 54 patients with lower extremity peripheral artery disease (PAD).
Cognitive impairment was assessed using Montreal  Cognitive Assessment Scale (MoCA), depressive symptoms -  PHQ-9 scale.
HRQoL was measured using Medical Outcome Survey Short Form version 2 (SF-36v2).
Results:
Median  MoCA  score  24  [23;26]  was  significantly  lower  in  patients  with  severe  CAS  than  in  patients  with  PAD  -  26
[25-28],(p=0.005; effect size r=0.3). There was no statistically significant difference of median PHQ-9 scores the in CAS group
(median PHQ-9 score 4.0 [5]) and in the PAD group (median PHQ-9 score 5.5 [7]), (p=0.08, effect size r=0.18). Mean SF-36v2
scores were similar in CAS and PAD groups except for bodily pain (p=0.001, Cohen's d value = 0.77) and vitality (p=0.02, Cohen's d
value = 0.49).
Conclusion:
In summary, our findings indicate that severe CAS could play a role in cognitive decline. Further studies should be conducted using
larger  patient  cohorts  without  ischemic  brain  lesions  and  with  balanced  vascular  risk  profiles  to  investigate  impact  of  CAS on
cognition. There was no association between severe CAS and depressive symptoms in the present study. As patients with severe CAS
did not exhibit physical symptoms, HRQoL was better for those patients than for patients with lower extremity PAD.
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1. INTRODUCTION
Atherosclerosis  is  a  chronic  systemic  inflammatory  disease  affecting  all  arteries  in  the  body  [1].  Age-adjusted
atherosclerotic cardiovascular disease (ACD) mortality rate trends have decreased globally, but the absolute number of
ACD deaths is increasing in part due to the growth and the aging of the population, making atherosclerosis a leading
cause of mortality world-wide [2]. The widespread occurrence of the atherosclerosis demands a closer look at how it
affects quality of life.
Carotid  artery  atherosclerosis  is  not  just  a  causal  risk  factor  of  ischemic  stroke  [3,  4],  it  also  appears  to  be  an
independent  risk factor  for  cognitive impairment  [5]  and may predispose patients  to  depressive symptoms and low
health related quality of life (HRQoL) [6]. The assessment of cognitive performance has been reported in patients with
severe carotid artery stenosis (CAS) [7], but the results do not show clear interdependency. It remains controversial [8],
whether patients with asymptomatic severe CAS suffer from cognitive impairment.
A relevant factor associated with atherosclerosis is depression. High prevalence of depression in cardiovascular
disease [9] and stroke patients [10] is well documented in literature. Considering reports of cognitive performance in
patients with asymptomatic carotid stenosis due to hypoperfusion, microemboli, altered cerebrovascular reactivity and
impaired regional functional connectivity [7], these pathogenetic mechanisms could theoretically also favour depressive
symptoms besides the current concept of “vascular depression” [11]. Therefore if CAS itself would promote cognitive
impairment and depressive symptoms, revascularisation may prevent not only cognitive decline and depression but also
improve quality of life.
The objectives of the present study were to assess the association between severe CAS and cognitive impairment,
frequency of depressive symptoms and status of HRQoL. We hypothesised that patients with severe carotid stenosis
would  have  worse  cognitive  performance,  depressive  symptoms  and  HRQoL  than  patients  with  lower  extremity
peripheral artery disease (PAD).
2. MATERIALS AND METHODS
2.1. Design and Study Population
The  study  involved  55  patients  undergoing  carotid  artery  endarterectomy  (CEA)  for  clinically  severe  carotid
stenosis  (≥  70% luminal  narrowing)  and  54  patients  with  lower  extremity  PAD undergoing  iliac  or  femoral  artery
revascularisation as a control group at the Pauls Stradins Clinical University Hospital from March 2016 to February
2017.
All consenting patients with severe CAS enrolled in this prospective exploratory study met the following inclusion
criteria: age 18 years or older, severe extracranial CAS ≥ 70% and lower extremity PAD. CAS was estimated with
computed  tomography  angiography  and  defined  according  to  North  American  Symptomatic  Carotid  Artery
Endarterectomy Trial (NASCET) criteria [12]; symptomatic carotid stenosis was considered if a minor stroke (National
Institute of Health Stroke Scale (NIHSS) <4, modified Rankin Scale 0 – 2 at the time of inclusion), transient ischemic
attack  (TIA)  or  Amaurosis  fugax  occurred  within  6  months;  asymptomatic  carotid  stenosis  was  considered  if
Asymptomatic  Carotid  Atherosclerosis  Study  criteria  were  met  [13].  Lower  extremity  PAD  was  defined  if  it  was
documented in previous medical reports or the patient had symptoms of claudication. Exclusion criteria were major
stroke (modified Rankin Scale III-V), patients with antidepressant therapy and progressive cerebral disease (tumour,
multiple sclerosis).
Fifty  four  consenting  patients  with  severe  PAD  undergoing  iliac  or  femoral  artery  revascularisation  served  as
control patients to match patients on demographic and cardiovascular risk factor variables. Severe PAD was defined as
lifestyle -  limiting claudication with inadequate response to guideline -  directed management and therapy [14].  All
control group patients underwent duplex ultrasound assessment of the carotid arteries and were included if CAS was
<50%. Control patients were excluded based on history of stroke, TIA or carotid artery revascularisation, antidepressant
therapy and progressive cerebral disease (tumour, multiple sclerosis).
2.2. Basic Characteristics
All patients were assessed 1-3 days before surgical management by a trained neurologist in a quiet and ambient
room  at  the  hospital.  Basic  demographic  characteristics  (age,  sex,  education),  anthropometric  and  lifestyle
characteristics  (weight,  height,  smoking),  data  on  comorbidities  (history  of  stroke  or  TIA,  coronary  artery  disease,
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arterial hypertension (AH), chronic heart failure, atrial fibrillation, diabetes mellitus, PAD), use of medications and
neurological examination were recorded on standardized form. Body mass index (BMI) was calculated as weight (kg)
divided by the square of  high in metres (m2).  Participants were classified as cigarette smokers if  they were current
smokers  or  had quit  smoking within  5  years  before  enrolment.  History of  TIA or  minor  stroke was collected from
previous medical records. Coronary artery disease was defined as a previous diagnosis of angina pectoris, myocardial
infarction. AH was defined as values ≥ 140mmHg systolic blood pressure and/or ≥90mmHg diastolic blood pressure or
current treatment with antihypertensive drugs [15]. Patients who had New York Heart Association (NYHA) class II to
III chronic heart failure were included [16]. Atrial fibrillation was defined as documented diagnosis of all patterns of
atrial  fibrillation  according  to  European  Society  of  Cardiology  guidelines  [17].  Diabetes  mellitus  was  defined  as  a
previous diagnosis of type I or type II diabetes or current use of oral blood-sugar-lowering drugs or insulin. PAD was
defined  according  to  American  Heart  Association/American  College  of  Cardiology  (AHA/ACC)  guidelines  [14].
Regular  use  of  antihypertensive  medications,  antiplatelet  drugs,  statins  or  other  hypolipidemic  drugs  and
hypoglicaemics  was  also  recorded  on  a  standardized  form.
A single neurologist evaluated cognitive performance and asked patients to complete questionnaires: Patient Health
Questionnaire - 9 (PHQ-9) and Medical Outcome Survey Short Form 36 version 2 (SF-36v2) in the presence of an
investigator; she was blinded to the basic characteristics of patient data.
2.3. Assessment of Cognitive Performance
As  Montreal  Cognitive  Assessment  Scale  (MoCA)  has  been  approved  as  a  valid  screening  tool  for  vascular
cognitive impairment [18 - 20], cognitive testing was performed using Latvian or Russian MoCA version, according to
the native language of the participant and instructions given by the authors [21]. It is a 10-minute cognitive screening
tool used to detect mild cognitive impairment. The MoCA scores range from 0-30 and are divided into 7 subscores:
visuospatial/executive (alternating trail-making, cube copy, clock drawing), naming (lion, rhinoceros, camel), attention
(forward and backward digit span, taping to the letter A, subtracting 7s from 100), language (sentence repetition, letter
fluency),  abstraction  (similarities  between  train  and  bicycle,  watch  and  ruler),  memory  (delayed  verbal  recall  of  5
words), orientation (to time and space) and an additional point is given to each patient who has educational experience
of 12 years or fewer. A final total score of 26 and above is considered normal [22].
2.4. Assessment of Depressive Symptoms
PHQ-9 is a well-validated measure that can establish a provisional depressive disorder diagnosis [23]. The PHQ-9
score ranges from 0 to 27 because each of the 9 items can be scored from 0 (“not at all”) to 3 (“nearly every day”). Cut-
points  5,  10,  15  and  20  represent  the  threshold  for  mild,  moderate,  moderately  severe  and  severe  depression,
respectively. PHQ-9 score of 10 or greater, which has sensitivity for major depression of 88%, a specificity of 88%, is
recommended  to  use  as  a  screening  cut-point  [24].  Therefore,  Latvian  and  Russian  versions  of  the  Patient  Health
Questionnaire (PHQ-9) depression scale [25] was used to assess depressive symptoms. Patients were categorized in two
groups according to PHQ-9 score. PHQ-9 scores lower than 10 denoted no relevant depressive symptoms. Scores of 10
or higher indicated relevant depressive symptoms.
2.5. Assessment of Health Related Quality of Life
HRQoL was assessed using the Medical Outcome Survey Short Form 36 version 2 (SF-36v2), Latvian and Russian
language versions [26].The SF-36v2 includes one favourably scored scale measuring each of eight health domains:
physical  functioning,  role  participation  with  physical  health  problems  (role-physical),  bodily  pain,  general  health,
vitality, social functioning, role participation with emotional health problems (role-emotional) and mental health. For
each item, scores are coded, summed and transformed into a scale from 0 (worst possible health state measured by the
questionnaire) to 100 (best possible health state). A difference of 5 to 10 points is considered a clinically important
change for an individual subject (a smaller difference may be important for group comparisons) [27]. In addition, the
SF-36v2 provides summary scales for overall physical and mental health, which are standardized to a population mean
of 50 and a standard deviation of 10 and for which individual differences of 2,5 to 5 points are considered clinically
meaningful [28]. SF-36 data of age-matched general Latvian population (age ≥ 66 years) [29] were used to compare
HRQoL of general population with severe CAS and PAD.
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2.6. Ethics Approval and Consent to Participate
The study protocol was approved by the corresponding local ethic committee of Riga Stradins University. Written
informed consent was obtained from all patients prior to study inclusion.
2.7. Statistical Analysis
Descriptive  statistics  were  used  to  analyse  the  demographics  and  clinical  characteristics  of  the  population.
Continuous variables were described as means (standard deviation (SD)) or median and interquartile range ([IQR]).
Categorical variables were presented as counts and percentages.
The  normal  distribution  of  data  was  tested  with  the  Kolmogorov-Smirnov  test.  Normally  distributed  data  were
analysed with t tests for independent samples. Continuous (non-Gaussian distribution) variables were compared with
the Mann-Whitney U test. To explore comparability of both groups (whether there are any potential cofounders that
could influence the results) univariate analysis was carried out for an association between both groups (Chi-square test
for categorical variables). A two-sided p-value < 0.05 was considered statistically significant. To understand whether
differences were statistically meaningful, Cramer's V (<0.3=small effect size, 0.3 - 0.5 = medium effect size, >0.5=large
effect  size)  for  Pearson  Chi-square  test,  Cochen's  d  value  (<0.5=small  effect  size,  0.5-0.8=medium  effect  size,
>0.8=large effect size)for t-test and r (<0.3=small effect size, 0.3-0.5=medium effect size, >0.5=large effect size) for
Mann-Whitney was used. Statistical analyses were performed using IBM SPSS Statistics(version 23 for Windows, IBM
Corp., Somers, NY, USA).
3. RESULTS
3.1. Characteristics of Patients
The study comprised of 55 patients with severe CAS and 54 matched control subjects with severe PAD. CAS and
control  subjects  were  balanced  in  regard  to  age,  gender,  BMI,  and  co-morbidities  such  as  coronary  artery  disease,
chronic  heart  failure,  atrial  fibrillation and diabetes  mellitus.  Statistically  significant  differences  were found across
groups for TIA or minor stroke, AH, smoking habit and use of medications, including antiplatelet and hypolipidemic
drugs. Diagnosis of AH seemed to be more prevalent in patients with severe CAS (p=0.001; Carmer's V = 0.367) but
compliance of AH treatment and maintenance of normal arterial blood pressure were similar in both groups (p=0.951;
Cramer's  V=0.146).  Control  subjects  with  severe  PAD  presented  a  higher  prevalence  of  smoking  habit  (p=0.02,
Cramer's V = 0,2), and lower compliance of medication treatment (p<0.05; Cramer's V= 0.2) although effect size of
statistically significant difference was small (Table 1).
Table 1. Demographic data and clinical characteristics of patients with severe CAS and control subjects with severe PAD.






(45-87) 0.768 Cochen's d = 0.34
Male 43 (78%) 40 (74%) 0.615
Previous Minor Stroke/TIA 11 (20%) 0 0.001 Cramer's V= 0.285
TIA/
Amaurosis Fugax 6 0
Minor Stroke 5 0
Coronary Disease 22 (40%) 15 (28%) 0.443 Cramer's V= 0.566
AH 54 (98%) 41 (76%) 0.001 Cramer's V= 0.367
Compliance of Hypertension Treatment 28 (52%) 21 (51%) 0.951 Cramer's V= 0.146
Chronic Heart Failure >2 NYHA 22 (40%) 15(28%) 0.178 Cramer's V = 0.120
Atrial Fibrillation 8 (14%) 5 (9%) 0.395 Cramer's V= 0.075
Diabetes Mellitus 6 (11%) 12 (22%) 0.112 Cramer's V= 0.148
Smoking Habit 35 (64%) 45 (83%) 0.02 Cramer's V= 0.221
BMI 26.8 (4.07) 25.27 (4.21) 0.093 Cochen's d= 0.369
Use of Antiplatelet Drugs 39 (71%) 27 (50%) 0.02 Cramer's V= 0.2
Use of Hypolipidemic Drugs 36 (65%) 17 (32%) 0.001 Cramer's V= 0.3
Data presented as mean (SD) or n (%)
CAS, carotid artery stenosis; PAD, lower extremity peripheral artery disease; SD, standard deviation; TIA, transient
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ischemic attack; AH, arterial hypertension; NYHA, New York Heart Association classification; BMI, body mass index
Comparison of cognitive performance between patients with carotid artery stenosis and lower extremity peripheral
artery disease.
Although both groups presented mean MoCA scores below the suggested cut-off score, mean MoCA scores 24.2
(2.77)were  significantly  lower  in  CAS patients  than  in  patients  with  PAD -  25.8  (2.28)  (p<0.01,  Cochen's  d  value
0.59).Complementary statistically significant difference with medium effect size was observed with median MoCA
scores (p=0.005; effect size r=0.3) Table (2). In our study, patients with CAS performed significantly worse on the
MoCA subtests of delayed recall (p=0.023, r=0.24).
Table 2. MoCA scores for patients with severe CAS and for control subjects with severe PAD.
CAS (n=55) PAD (n=54)
p value Effect Size, R
Median Q1 Q3 Median Q1 Q3
MoCA Total Score 24 23 26 26 25 28 0.005 0.3
MoCA Subtests:
VSE 4 3 5 4 4 5 0.128 0.16
Naming 3 3 3 3 3 3 0.419 0.08
Attention 5 5 6 6 5 6 0.142 0.16
Language 2 1 2 2 1 2 0.661 0.05
Abstraction 2 1 2 2 1 2 0.773 0.03
Delayed Recall 2 1 4 3.5 2 5 0.023 0.24
Orientation 6 6 6 6 6 6 0.684 0.04
CAS,  carotid  artery  stenosis;  PAD,  lower  extremity  peripheral  artery  disease;  MoCA,  Montreal  Cognitive  Assessment  Scale;  VSE,
visuospatial/executive  functions
Comparison of depressive symptoms between patients with carotid artery stenosis and lower extremity peripheral
artery disease.
According to the accepted threshold of the PHQ-9 (score≥10) for depressive symptoms, the difference of frequency
was not statistically significant between both groups Table (3). Further, there was no statistically significant difference
of median PHQ-9 scores in the CAS group (median PHQ-9 score 4.0 [5]) and in the PAD group (median PHQ-9 score
5.5 [7]), (p=0.08, effect size r=0.18).
Table 3. The frequency of PHQ-9 scores in patients with CAS and in patients with PAD.
PHQ-9 scores
p Value Cramer's V
1-4 5-9 ≥10
CAS (n=55) 32 (58%) 15 (27%) 8 (15%)
0.168 0.168
PAD (n=54) 24 (44%) 13 (24%) 17 (32%)
PHQ-9, Patient Health Questionnaire - 9; CAS, carotid artery stenosis; PAD, lower extremity peripheral artery disease;
Comparison of HRQoL between patients with carotid artery stenosis and lower extremity peripheral artery disease.
Mean SF-36v2 scores for  bodily pain and vitality were significantly lower in patients  with severe PAD than in
patients  with  severe  CAS  (p=0.001  and  p=0.02).  The  lowest  SF-36v2  mean  scores  in  patients  with  CAS  were  for
general health and the highest for social functioning and mental health. The lowest scores in patients with severe PAD
were for physical functioning, role-physical, bodily pain and general health, but the highest was for social functioning
and role-emotional. Comparing mean SF-36v2 scores of patients with CAS with those of the general Latvian population
aged  ≥66  years,  there  was  no  statistically  significant  difference  observed.  Mean  SF-36v2  scores  for  physical
functioning, role-physical and bodily pain were significantly lower in patients with PAD than in the Latvian population
under age 66 years (Cohen's d value 0.7) (Table 4).
Table 4. Mean SF-36v2 scores in patients with severe CAS, severe PAD and in the Latvian population ≥ 66 years sample.
SF-36v2 Subscales CAS(n=55) PAD (n=54)






Population ≥ 66 Years#
Mean SF-36v2
PAD vs. Latvian
Population ≥ 66 Years^
PF 55.3 (23.7) 46.4 (21.6) 63.4(25.5) 0.39 0.33 0.7
RP 51.5 (25.6) 42.8 (25.8) 60.9(26.4) 0.34 0.36 0.69
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SF-36v2 Subscales CAS(n=55) PAD (n=54)






Population ≥ 66 Years#
Mean SF-36v2
PAD vs. Latvian
Population ≥ 66 Years^
BP 55.8 (25.7) 37.7 (20.9) 55.5(24.7) 0.77 <0.1 0.78
GH 48.4 (12.0) 43.4 (15.3) 43.7(19.5) 0.36 0.29 <0.1
VT 60.6 (15.6) 51.4 (21.2) 55.4(18.4) 0.49 0.3 0.2
SF 68.6 (25.4) 59.8 (31.4) 70.5(24.6) 0.31 <0.1 0.38
RE 64.2 (25.2) 59.9 (29.1) 70.4(25.9) 0.16 0.24 0.38
MH 68.5 (14.8) 61.8 (20.2) 61.1(17.8) 0.38 <0.1 0.45
SD, standard deviation; CAS, carotid artery stenosis; PAD, lower extremity peripheral artery disease; PF - Physical functioning; RP - role physical;
BP - bodily pain; GH - general health; VT - vitality; SF - social functioning; RE - role emotional; MH - mental health
*Comparing mean SF36v2 between CAS un PAD groups (Cohen's d  value);  #comparing mean SF36v2 between CAS and Latvian age matched
population (Cohen's d value); ^comparing mean SF36v2 between PAD and Latvian age matched population (Cohen's d value).
In mean SF-36v2 scores related to gender and age, there were no statistically significant differences in the CAS or
PAD groups.  In  analysis  of  whether  cognitive  impairment  (MoCA< 26)  had  an  association  with  HRQoL either  in
patients with CAS or PAD, no significant differences were noted between groups. An association between depressive
symptoms and impaired HRQoL was observed in both groups. Mean SF-36v2 scores for bodily pain, general health,
vitality,  social  functioning,  role-emotional  and  mental  health  were  significantly  lower  in  patients  with  depressive
symptoms in CAS group Table (5). Mean SF-36v2 scores for general health, vitality, role-emotional and mental health
were significantly lower in patients with depressive symptoms in the severe PAD group, but there was no significant
difference  of  mean  SF-36v2  scores  for  role-physical  and  social  functioning  regardless  of  whether  the  patient  had
depressive symptoms (Table 6).
Table 5. Mean SF-36v2 scores in patients with severe CAS with and without depressive symptoms.




(n=7) P Value Cohen's d Value
PF 56,4 (24.5) 48.8 (18.1) 0.4 0.35
RP 53.6 (26.1) 39.1 (19.7) 0.14 0.63
BP 59.1 (25.9) 36.4 (12.7) 0.019 1.11
GH 49.9 (11.6) 39.4 (10.5) 0.02 0.95
VT 64.6 (12.7) 36.7 (7.0) <0.001 2.72
SF 73.1 (24.3) 42.2 (13.2) 0.001 1.58
RE 67.4 (25.8) 45.8 (8.9) 0.024 1.12
MH 71.1 (14.1) 53.1 (9.2) 0.001 1.51
CAS, severe carotid artery stenosis; PHQ-9, Patient Health Questionnaire - 9; PF - Physical functioning; RP - role physical; BP - bodily pain; GH -
general health; VT - vitality; SF - social functioning; RE - role emotional; MH - mental health
Table 6. Mean SF-36v2 scores in patients with severe PAD with and without depressive symptoms.
PAD Patients, SF-36v2 Mean Scores, (SD)
PHQ-9 <10 (n=22) PHQ-9 ≥10(n=10) P value Cohen's d Value
PF 50.2 (24.1) 38.0 (3.7) 0.14 0.71
RP 46.0 (26.7) 35.6 (23.6) 0.299 0.41
BP 41.5 (22.3) 29.3 (15.3) 0.13 0.64
GH 48.7 (13.1) 31.7 (13.5) 0.002 1.28
VT 57.4 (20.6) 38.1 (16.3) 0.014 1.04
SF 63.1 (33.1) 52.5 (27.5) 0.386 0.35
RE 66.7 (30.1) 45.0 (21.2) 0.049 0.83
MH 69.5 (18.1) 44.5 (12.8) <0.0001 1.60
CAS, severe carotid artery stenosis; PHQ-9, Patient Health Questionnaire - 9; PF - Physical functioning; RP - role physical; BP - bodily pain; GH -
general health; VT - vitality; SF - social functioning; RE - role emotional; MH - mental health
(Table 4) contd.....
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4. DISCUSSION
Severe CAS is associated with increased risk for cognitive impairment [7], [30] despite the fact that some studies
have  failed  to  identify  cognitive  abnormalities  in  patients  with  this  condition  [31].  It  is  considered  that  cognitive
impairment  in  patients  with  symptomatic  severe  CAS  is  in  the  context  of  the  acute  stroke  lesion  [32,  33],  but
association  of  asymptomatic  severe  CAS  and  cognitive  impairment  is  not  yet  clear.  One  probable  pathogenetic
mechanism  of  cognitive  impairment  in  asymptomatic  severe  CAS  may  be  due  to  decreased  cerebral  blood  flow
(hypoperfusion, microemboli, altered cerebrovascular reactivity) [7]. Another assumption of disputable mechanisms of
cognitive impairment is whether carotid stenosis is an indicator or marker for underlying multiple vascular risk factors
that predispose patients to cognitive impairment due to intracranial atherosclerosis [34, 35]. Therefore, taking these
considerations into account, the control group in our study was chosen to present the same vascular risk factors as those
in the severe CAS group, with only one difference: in the control group CAS was <50%. Although overall the vascular
risk factors were similar between the two groups in our study, the frequency of previous minor stroke or TIA, AH,
smoking habits and medication adherence were significantly different (p< 0.05). However, the effect size of statistical
significance  was  small  for  each  of  these  factors,  with  the  exception  for  AH.  We therefore  reasoned  that  these  two
groups were comparable in both demographics and vascular risk factors.
The current study found that median MoCA scores were lower in patients with CAS than in those in the control
group. This suggests that patients with advanced atherosclerosis and severe CAS may be at higher risk for cognitive
impairment than patients with advanced atherosclerosis without CAS. However, because of the known associations of
cognitive impairment with minor stroke and TIA, our data should be interpreted with caution, despite the fact that in
severe CAS group the number of patients with minor stroke or TIA (n=11; 20%) and the corresponding effect size of
statistical significance (Cramer's V = 0.285) were small. Several studies have evaluated cognitive impairment after TIA
or minor ischemic stroke. The aims of those studies were similar - to evaluate the frequency of cognitive impairment in
patients with TIA [36] or in stroke patients with no significant disabilities using either modified Rankin Scale (mRS)
[33] or NIHSS [37] for clinical  neurological  assessment.  There were differences between the studies in the sample
characteristics, clinical assessment methods used and timing of cognitive testing, as well as in the definition of TIA
(clinical versus imaging based diagnosis of TIA). Nevertheless the conclusions of the studies were consistent: cognitive
impairment was common in patients who had suffered an ischemic stroke and had a successful clinical recovery with no
functional disability. Additionally, at least one-third of TIA patients had impairment of one or more cognitive domains
[38].  However  there  is  still  lack  of  comparable  studies  and  available  data  on  risk  factors  or  potential  causes  and
underlying mechanisms of cognitive dysfunction after TIA. Another reason to interpret the results of the current study
with caution is the high prevalence of AH in the CAS group. It is known that high blood pressure is a strong risk factor
for white matter lesion (WML) [39] and data suggests that WMLs could lead to cognitive decline and may play a role in
the aetiology of dementia [40]. However, there are data that implies that AH treatment could reduce WML progression
[39]. Besides, it is also known that AH in small portion of patients with bilateral severe CAS may have a adjusting role
in hemodynamics of cerebral perfusion [41], suggesting that in the context of CAS, it may be a protective factor against
cognitive dysfunction.  For  these reasons,  the influence of  AH on cognitive decline in  our  study remains uncertain.
Finally, patients had modifiable risk factors for vascular disease that have been shown to increase the risk for cognitive
impairment  [34].  Although  the  prevalence  of  these  risk  factors  was  similar  between  the  experimental  and  control
groups, they may have influenced cognitive performance in our study, thus the sole impact of severe CAS on cognition
may be affected or left obscure. Nevertheless, these data could be considered because, besides being the best medical
treatment for CAS, revascularisation may not only prevent risk of stroke but also improve [42 - 44] or provide some
protection against cognitive decline in the elderly [31], [45]. When the results of our study are compared with other
studies  that  used  MoCA  as  a  screening  tool  to  assess  cognitive  performance  [45],  [46],  there  were  some  slight
discrepancies, which may be due to disparities in the quantification of CAS and calculation of mean MoCA scores.
However,  the results were consistent that cognitive impairment was present in patients with severe CAS [47].  This
finding was confirmed by additional studies using sensitive standardised complex neuropsychological tests [8], [48].
Depressive symptoms are frequently found in older patients with symptomatic severe CAS [49], but it is unknown
whether there is a direct causal relationship between severe CAS and depressive symptoms [50] or whether depression
is a consequence of the cerebrovascular atherosclerosis sequelae [51 - 54]. Although the present study did not identify a
statistically significant difference in the frequency of relevant depressive symptoms between the CAS and PAD groups,
there was a trend towards more depressive symptoms with higher PHQ-9 scores in patients with PAD. By contrast,
similar studies have found that relevant depressive symptoms were more common in patients with CAS than in those
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with PAD [49], [50]. One possible reason for this discrepancy could be the selection bias for the PAD group in our
study. The patients in the PAD group had more advanced PAD and experienced symptoms that interfered with their
daily activities. This was confirmed by lower mean scores on the HRQoL evaluation for physical functioning, general
health and mental health perception (depressive symptoms and hopeless feeling) for the PAD patients compared to the
CAS patients. This is consistent with recently published data, which found that patients with increased atherosclerosis
and diminished walking function, were at increased risk for depression [55]. In our study, patients taking antidepressant
therapy were excluded because evidence suggests that major depressive disorder and active pharmacological therapy
both may affect cognitive function [56].
To further evaluate HRQoL, patients with severe CAS and those with PAD were compared to healthy age matched
Latvian population. Evaluating HRQoL, there was no significant difference between the Latvian population under 66
years  of  age  and patients  with  severe  CAS.  By contrast,  patients  with  PAD had significantly  lower  mean SF-36v2
scores for physical functioning, role-physical and bodily pain than did the Latvian population and significantly lower
scores for bodily pain and vitality than did patients in the CAS group. There were no associations of probable impact of
age, gender or cognitive impairment on HRQoL scores in the CAS and PAD groups. The analysis of HRQoL in patients
with and without depressive symptoms in each group showed that the mean SF-36v2 scores were lower for general
health,  vitality,  role-emotional  and  mental  health  for  patients  with  depressive  symptoms  in  CAS  and  PAD  groups
compared  to  those  without  depressive  symptoms.  These  results  demonstrate  that  depression,  which  has  a  higher
incidence  in  patients  with  cardiovascular  diseases  [57],  could  lead  to  a  poorer  HRQoL.  Comparing  mean  SF-36v2
scores in patients with depressive symptoms, lower scores for physical functioning, bodily pain, general health and
mental health were achieved by patients in the PAD group than by patients in the CAS group. These results could be
explained by bodily pain and impairment of physical functioning experienced by patients with severe PAD as they have
more physically unpleasant symptoms than patients with severe CAS.
Several studies have assessed HRQoL in patients with CAS and PAD with varying results. Some studies reported
poorer HRQoL in patients with CAS than in the general population [58], [59]. This contradicts the results of our study,
in which there were no significant differences in mean SF-36v2 scores between the severe CAS group and the age-
matched Latvian population. This discrepancy could be explained by differences in HRQoL questionnaires, control
groups  (general  rather  than  age-matched  population)  and  the  presentation  of  the  results  (median  rather  than  mean
values). The Athero-Express biobank study [58] evaluated HRQoL in patients with PAD compared with healthy Dutch
age-matched individuals. The findings from this study were consistent with those from our study, demonstrating poorer
HRQoL in patients with PAD. However, the Dutch study did not identify a significant difference in HRQoL between
patients with CAS and those with PAD, whereas in our study, scores for bodily pain and vitality were significantly
lower in the PAD group. The reason for the discrepancy is likely that in our study, all patients in the severe CAS group
also had mild to moderate PAD, whereas in the control group, all patients had significant clinical symptoms of PAD
with indications for revascularisation.
The PARTNERS study compared HRQoL among patients with PAD and PAD together with other cardiovascular
disease  (CVD).  This  study found that  HRQoL was  lower  in  the  PAD-other-CVD patient  group [60].  These  results
contradict those of our study which found that patients with severe CAS and mild to moderate lower extremity PAD did
not  have worse HRQoL compared to  those with  severe  PAD alone.  The PARTNERS study [60]  included not  only
patients with stroke or TIA, but also those with symptomatic coronary artery disease in the PAD-other-CVD group.
Thus, the underlying lower extremity or cardiac symptoms may have influenced impairment of HRQoL, especially the
physical components. There are no physical symptoms associated with CAS that could interfere with daily activities and
therefore significantly influence HRQoL.
Our results identified an association between severe CAS and cognitive impairment, and between severe PAD and a
tendency towards increased frequency of depressive symptoms and lower HRQoL scores. Health care specialists should
be aware of these findings when managing patient care because patients may benefit not only from cardiovascular risk
factor management but also from additional physical and emotional support that may help to improve their activities of
daily living [58]. Additionally, this information can help in decision-making for revascularisation therapy in patients
with CAS.
Several limitations of this study should be acknowledged. First, this was a cross-sectional study with a relatively
small sample size and a control group size that did not exceed the case sample. Second, there was a higher prevalence of
TIA, minor stroke and AH in the CAS group which may have negatively influenced cognitive performance. Future
studies should involve recruitment of more asymptomatic CAS and control patients with a better balance of vascular
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risk  factors.  Additionally,  brain  imaging  should  be  performed  in  both  groups  to  evaluate  the  presence  of  WMLs.
Finally, the control group exhibited more severe clinical symptoms of PAD than those in the CAS group, which may
have influenced the HRQoL data and the frequency of depressive symptoms. Therefore, further studies are needed to
explore the influence of severe CAS on cognitive function and development of depressive symptoms using a healthy,
age-matched control group.
CONCLUSIONS
In summary, our findings indicate that severe CAS could play a role in cognitive decline. Further studies should be
conducted  using  larger  patient  cohorts  without  ischemic  brain  lesions  and  with  balanced  vascular  risk  profiles  to
investigate impact of CAS on cognition. There was no association between severe CAS and depressive symptoms in the
present study. As patients with severe CAS did not exhibit physical symptoms, HRQoL was better for those patients
than for patients with lower extremity PAD.
LIST OF ABBREVATIONS
HRQoL = Health related quality of life;
CAS = Carotid artery stenosis;
PAD = Lower extremity peripheral artery disease
MoCA = Montreal Cognitive Assessment
PHQ-9 = Patient Health Questionnaire – 9
SF-36v2 = Medical Outcome Survey Short Form version 2
ACD = Atherosclerotic cardiovascular disease
CAE = Carotid artery endarterectomy;
NASCET = North American Symptomatic Carotid Endarterectomy Trial;
NIHSS = National Institute of Health Stroke Scale
TIA = Transient ischemic attack
ACAS = Asymptomatic Carotid Atherosclerosis Study
BMI = Body mass index
NYHA = New York Heart Association classification
AHA/ACC = American Heart Association/ American College of Cardiology Foundation
SD = Standard deviation
IQR = Interquartile range
VSE = Visuospatial/executive functions
PF = Physical functioning
RP = Role physical
BP = Bodily pain
GH = General health
VT = Vitality
SF = Social functioning
RE = Role emotional
MH = Mental health
PARTNERS = Peripheral Arterial Disease Awareness, Risk and Treatment: New Resources of Survival Program
CVD = Cardiovascular disease
mRS = Modified Rankin Scale
AH = Arterial hypertension
WML = White matter lesion
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